{"id":878068,"date":"2025-08-21T14:03:06","date_gmt":"2025-08-21T18:03:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/"},"modified":"2025-08-21T14:03:06","modified_gmt":"2025-08-21T18:03:06","slug":"silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/","title":{"rendered":"Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal"},"content":{"rendered":"<div class=\"mw_release\">\n<hr \/>\n<p>\n        <b><br \/>\n          <i>Manuscript featured in leading open-access scientific journal Alzheimer\u2019s Research &amp; Therapy<\/i><br \/>\n        <\/b>\n      <\/p>\n<p>SARASOTA, FL, Aug.  21, 2025  (GLOBE NEWSWIRE) &#8212;  Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or \u201cthe Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced the publication of preclinical research for its Alzheimer\u2019s disease (AD) therapeutic, SPC-14, in Alzheimer\u2019s Research &amp; Therapy, an international open-access peer-reviewed scientific journal known as the major forum for translational research into AD.<\/p>\n<p>The study, titled \u201cCombinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer\u2019s disease,\u201d details research methods and results indicating that the combined administration of (R,S)-ketamine with prucalopride is a novel multi-modal therapeutic strategy to treat cognitive decline in AD. \u00a0\u00a0The Company\u2019s CEO, Eric Weisblum, was a co-author of the study and the project was supported by a sponsored research program from the\u00a0 Company. <\/p>\n<p>\u201cThe results of this study showed that the SPC-14 formulation improved cognitive decline by increasing memory retrieval in a fear conditioning model in mice. The conclusion identifies SPC-14 as a promising drug combination for therapeutic use in AD and contributes to advancements in discovering targeted therapies for the treatment of dementia in AD,\u201d said Silo CEO Eric Weisblum. <\/p>\n<p>SPC-14 was developed under a sponsored research agreement with Columbia University.\u00a0In 2024, Silo entered into an exclusive global license agreement with Columbia University under which it is authorized to further develop, manufacture, and commercialize SPC-14.<\/p>\n<p>SPC-14 addresses a vast Alzheimer\u2019s disease treatment market projected to grow to $30.8B\u00a0in 2033, at 18.8%\u00a0CAGR.<sup>1<\/sup><\/p>\n<p>\n        <strong>About SPC-14<\/strong>\n      <\/p>\n<p> SPC-14 is a novel intranasal therapeutic that targets glutamate receptor NDMAR and serotonin type 4 receptor 5HT4 to treat cognitive and neuropsychiatric symptoms in Alzheimer\u2019s disease. In the latest small animal preclinical study, SPC-14 was effective against LH (luteinizing hormone) stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia, a measure of anxiety.<\/p>\n<p>\n        <strong>About Silo Pharma<\/strong>\n      <\/p>\n<p>Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company\u2019s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer\u2019s disease and multiple sclerosis. Silo\u2019s research is conducted in collaboration with leading universities and laboratories.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=atEbNBiV-nQr8g1WqbyNwzIMj65l5a2dU9d_hr8LD9tcl5ZmLhZuwQb7AxjqT9ped5-DFHTANL-kWLEBxKnuA8gznbCeZ_izDiEDEtPg2Rs=\" rel=\"nofollow\" target=\"_blank\">silopharma.com<\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This news release contains &#8220;forward-looking statements&#8221; within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words \u201ccould\u201d, \u201cbelieve\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201ccontinue\u201d, \u201cpredict\u201d, \u201cpotential\u201d, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (\u201cSilo\u201d or \u201cthe Company\u201d) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company\u2019s technology platforms, retaining and expanding the Company\u2019s customer base, fluctuations in consumer spending on the Company\u2019s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.<\/p>\n<p>\n        <strong>Contact<\/strong><br \/>\n        <br \/> 800-705-0120<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AufDS6AyDsn0r1x3-gJnCMaWnsOfOLckIA3LgLhO1clh1xfMPxUvu8QATI-UNkbgMefjU_z1dPtdlcERp4W2t5pjZUqriM5SwDmt0sqX4inZmJLOiw6lyEya1uBSiGu2JJUqLfLUIlHn4QBTPiWi3uMmKPR8yPUj122e2_ArD2EAmEbCW4HBwqU5BuJf8EqUsmoPlzAbNQBolagr6utRA5sfmT4pL9GsK5uJOct8VGnXz1aI7WUx8mcqsMcM-lLHpOD-mtZ0Y5grEeGMaKllVs6FK885F3LgUHpLtIZu3X8vQZq-F1so1zgrxFfwkYouNfA5gqY9rrgdy8f63RcPGlt5T_Kse5MLayCI3Je2Iv6acHFgvOIPlH7heJMD6gH5VwEc3ugTnq0h7OaCBzIMpjzL1oAACpxQQs8H0ewsCRXlhLgEnz9Qlinau9mxWrVyknWIEudgPXO4Fc5KiQPl22ZtqiwVnMRXItvep75rzBlsC8f3_20g_P2Sb2bQ8wUUZtm0yIysCnbzllh3oxtaTbE7BNBrpgxkNdBIVyYRoIzvoaRNqbVm7nKU_8_Ov1K1bxBmila4RaAAGnlRly2sCxhrXTlH6GI9oS85TnVmaUna2PKWYvpA-665vQ82Co0bO1OajTYXR_AvSCWTRmdr7uTgtY-BgqKmshFoOtS47ajhEiE34uBKeTtHWtwm4v82ga80yStOTnLsGCvmsh0b75NohpCw5g7dREzmKeRjv6FzGziGBMJ7637FwroXx4KkK5yfcKNdCgxWQcKPqxrlMuhkqWt5P91f-jjiV9cJnki4fld5q2kKKyOOHUJetp88BH2biNJaLuI85TwtjRD1EWT1hi1QY8L7prFK9GNRHFltma5ANoYtrvqwW8g-2ZpCTGGsUN4RiZI9ObfQ1MFKCBWdC4Y5RTPuk8oy3oyaEf9_NEKU4mxcZajyst43UXdtNP8GKSAM9VzHbDPseOVQ7iXHcDc4TKcFnm-eEoEKo9K1HZp5nT_v2sqHIkAiSCxf1wDRtyoZXecwXQQVQXs03zY2QGbqXknlAf100uXIiBRFxjAmTDJSP7RxjjyQ3movwCHzcH0nZJ_b5sphGnjfSckm4B3Nqj3rWmm_ZhD7KN7H1MBHf_thxtBFjIQb1oPBcLJxiabj1wtMVHHYzhx1Gm2tBab3EjWngbSxyuyeHm21jY-XIUqn0hIVdpMR9uaQ\" rel=\"nofollow\" target=\"_blank\">investors@silopharma.com<\/a><\/p>\n<p>\n        \n      <\/p>\n<p>\n        <sup>1<\/sup> Market.us, Alzheimer\u2019s Disease Therapeutics Market Value to Reach USD 30.8 Billion by 2033 | Driven by the Advancements in Neurological Research. January 2024.<\/p>\n<p>\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjIxNiM3MTEwMTk3IzUwMDA2OTMzOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWViMzFiOWEtMWYzMC00ZWQ2LWFiYTgtMTQxMDU4YTk4ODJjLTUwMDA2OTMzOS0yMDI1LTA4LTIxLWVu\/tiny\/Silo-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Manuscript featured in leading open-access scientific journal Alzheimer\u2019s Research &amp; Therapy SARASOTA, FL, Aug. 21, 2025 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or \u201cthe Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced the publication of preclinical research for its Alzheimer\u2019s disease (AD) therapeutic, SPC-14, in Alzheimer\u2019s Research &amp; Therapy, an international open-access peer-reviewed scientific journal known as the major forum for translational research into AD. The study, titled \u201cCombinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer\u2019s disease,\u201d details research methods and results indicating that the combined administration of (R,S)-ketamine with prucalopride is a novel multi-modal therapeutic strategy to treat cognitive decline in AD. \u00a0\u00a0The Company\u2019s CEO, Eric &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-878068","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Manuscript featured in leading open-access scientific journal Alzheimer\u2019s Research &amp; Therapy SARASOTA, FL, Aug. 21, 2025 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or \u201cthe Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced the publication of preclinical research for its Alzheimer\u2019s disease (AD) therapeutic, SPC-14, in Alzheimer\u2019s Research &amp; Therapy, an international open-access peer-reviewed scientific journal known as the major forum for translational research into AD. The study, titled \u201cCombinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer\u2019s disease,\u201d details research methods and results indicating that the combined administration of (R,S)-ketamine with prucalopride is a novel multi-modal therapeutic strategy to treat cognitive decline in AD. \u00a0\u00a0The Company\u2019s CEO, Eric &hellip; Continue reading &quot;Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-21T18:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjIxNiM3MTEwMTk3IzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal\",\"datePublished\":\"2025-08-21T18:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\\\/\"},\"wordCount\":634,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNjIxNiM3MTEwMTk3IzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\\\/\",\"name\":\"Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNjIxNiM3MTEwMTk3IzUwMDA2OTMzOQ==\",\"datePublished\":\"2025-08-21T18:03:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNjIxNiM3MTEwMTk3IzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNjIxNiM3MTEwMTk3IzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal - Market Newsdesk","og_description":"Manuscript featured in leading open-access scientific journal Alzheimer\u2019s Research &amp; Therapy SARASOTA, FL, Aug. 21, 2025 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or \u201cthe Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced the publication of preclinical research for its Alzheimer\u2019s disease (AD) therapeutic, SPC-14, in Alzheimer\u2019s Research &amp; Therapy, an international open-access peer-reviewed scientific journal known as the major forum for translational research into AD. The study, titled \u201cCombinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer\u2019s disease,\u201d details research methods and results indicating that the combined administration of (R,S)-ketamine with prucalopride is a novel multi-modal therapeutic strategy to treat cognitive decline in AD. \u00a0\u00a0The Company\u2019s CEO, Eric &hellip; Continue reading \"Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-21T18:03:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjIxNiM3MTEwMTk3IzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal","datePublished":"2025-08-21T18:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/"},"wordCount":634,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjIxNiM3MTEwMTk3IzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/","name":"Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjIxNiM3MTEwMTk3IzUwMDA2OTMzOQ==","datePublished":"2025-08-21T18:03:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjIxNiM3MTEwMTk3IzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjIxNiM3MTEwMTk3IzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-alzheimers-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-journal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma\u2019s Alzheimer\u2019s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/878068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=878068"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/878068\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=878068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=878068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=878068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}